News
Video
Author(s):
Insight into the typical response to first-line chemotherapy in advanced endometrial cancer and the clinical factors that influence treatment outcomes, with a focus on improving therapies for this high-risk cohort.
Dostarlimab With Carboplatin/Paclitaxel Shows Survival Benefits in dMMR/MSI-H Endometrial Cancer
Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers
Overcoming Adversity and Achieving the American Dream in Cancer Care
Simeone and Fakih Detail Research Objectives With A2B530 in CEA-Expressing Solid Tumors
Long-Term Findings Clarify Role of Estrogen Therapy on Ovarian/Endometrial Cancer Incidence
Mirvetuximab Soravtansine Plus Pembrolizumab Generates Reponses in pMMR FRα+ Serous Endometrial Cancer
MammaPrint High 2 Indication Could Be Predictive Biomarker for Immunotherapy in HR+/HER2– Early Breast Cancer
Linvoseltamab Generates Efficacy Similar to That Seen With Teclistamab in R/R Myeloma
Pembrolizumab With Platinum-Based Therapy is Safe and Efficacious in PSCC